<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343782</url>
  </required_header>
  <id_info>
    <org_study_id>VinmecRISCGT70</org_study_id>
    <nct_id>NCT03343782</nct_id>
  </id_info>
  <brief_title>Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes</brief_title>
  <acronym>ASD2</acronym>
  <official_title>Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type 2 Diabetes: An Open-label, Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Research Institute of Stem Cell and Gene Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Research Institute of Stem Cell and Gene Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of autologous bone
      marrow-derived mesenchymal stem cells transplantation in the treatment of type 2 diabetes
      mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bone marrow-derived mesenchymal stem cells have the immunosuppressive effect and secrete a
      variety of cytokines, improve the microenvironment of diabetic patients, targeting insulin
      resistance tissue, ameliorate the metabolic disorder of islet damage, protect and
      regeneration of the islet beta cells; reduce high blood sugar.The purpose of this study is to
      evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem
      cells transplantation in treatment 30 patients with type 2 diabetes mellitus at Vinmec
      International Hospital, Hanoi, Vietnam
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>30 patients were randomly assigned into 2 groups for injection (intravenous injection or dorsal pancreatic artery infusion).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Reduction of insulin dose requirement by â‰¥50% in both groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Number of adverse events in both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Change from baseline in fasting glucose over time between two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c) level</measure>
    <time_frame>up to the 12-month period following treatment</time_frame>
    <description>Improvement of HbA1c level as compared to baseline between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intravenous injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 15 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells by using intravenous injection and undergoing 2 treatment with 6 months interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dorsal pancreatic artery infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 15 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells by using the dorsal pancreatic artery and undergoing 2 treatment with 6 months interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Expanded autologous bone marrow-derived mesenchymal stem cell</intervention_name>
    <description>Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure</description>
    <arm_group_label>Intravenous injection</arm_group_label>
    <arm_group_label>Dorsal pancreatic artery infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between age 30 and 70 years.

          -  Hemoglobin A1c (HbA1c) is ranged from 7.5% to 9% at baseline.

          -  Type 2 diabetes duration 5 years or more.

          -  Before the screening, joint or combined with insulin, oral medications to treat more
             than 3 months.

          -  Who signed the informed consent form.

        Exclusion Criteria:

          -  Type 1 diabetes.

          -  Chronic disease or severe disease, including cancer, severe heart disease, kidney
             disease, liver disease, etc.

          -  According to the medical doctor's judgement, may endanger the safety of the subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vinmec Research Institute of Stem Cell and Gene Technology</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liem T Nguyen, MD, PhD</last_name>
      <phone>(+84 4) 3 974 3556</phone>
      <phone_ext>1420</phone_ext>
      <email>v.liemnt@vinmec.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <results_reference>
    <citation>Bhansali A, Asokumar P, Walia R, Bhansali S, Gupta V, Jain A, Sachdeva N, Sharma RR, Marwaha N, Khandelwal N. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant. 2014;23(9):1075-85.</citation>
    <PMID>23561959</PMID>
  </results_reference>
  <results_reference>
    <citation>Sood V, Mittal BR, Bhansali A, Singh B, Khandelwal N, Marwaha N, Jain A. Biodistribution of 18F-FDG-Labeled Autologous Bone Marrow-Derived Stem Cells in Patients With Type 2 Diabetes Mellitus: Exploring Targeted and Intravenous Routes of Delivery. Clin Nucl Med. 2015 Sep;40(9):697-700. doi: 10.1097/RLU.0000000000000850.</citation>
    <PMID>26164170</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446.</citation>
    <PMID>24759263</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2017</study_first_submitted>
  <study_first_submitted_qc>November 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>BM mesenchymal stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

